

Is There Evidence for the Presence and Relevance of the Squamous Cell Carcinoma? Hints From an Immunohistochemistry Study

Journal of Oral and Maxillofacial Surgery

75, 969-977

DOI: [10.1016/j.joms.2016.11.006](https://doi.org/10.1016/j.joms.2016.11.006)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4. <i>Biochemistry and Biophysics Reports</i> , 2018, 13, 123-128.	0.7	4
2	Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas. <i>BMC Cancer</i> , 2018, 18, 823.	1.1	12
3	Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 2484-2491.	0.9	33
4	High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature. <i>Cell Proliferation</i> , 2019, 52, e12537.	2.4	43
5	Oral Carcinogenesis and Malignant Transformation. <i>Head and Neck Cancer Clinics</i> , 2019, , 27-66.	0.0	11
6	The prognostic value of immune checkpoints in oral squamous cell carcinoma. <i>Oral Diseases</i> , 2019, 25, 1435-1445.	1.5	33
7	PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 546-554.	1.1	53
8	Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence. <i>Pathology and Oncology Research</i> , 2020, 26, 735-742.	0.9	24
9	An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. <i>Oral Diseases</i> , 2020, 26, 511-526.	1.5	44
10	Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 1855-1869.	1.2	12
11	The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis. <i>Pathology Research and Practice</i> , 2020, 216, 152768.	1.0	20
12	Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review. <i>Cancers</i> , 2020, 12, 1937.	1.7	48
13	PD-L1 in squamous cell carcinoma of the oral tongue shows gender-specific association with prognosis. <i>Oral Diseases</i> , 2020, 26, 1414-1423.	1.5	7
14	Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. <i>Scientific Reports</i> , 2020, 10, 9705.	1.6	57
15	Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. <i>Oral Oncology</i> , 2020, 106, 104722.	0.8	49
16	Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. <i>Archives of Oral Biology</i> , 2020, 114, 104717.	0.8	17
17	Clinicopathological and prognostic significance of PD-L1 in oral cancer: A preliminary retrospective immunohistochemistry study. <i>Oral Diseases</i> , 2021, 27, 173-182.	1.5	23
18	PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2021, 49, 118-125.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Low PDL1 Expression in Tumour Infiltrating Lymphocytes Predicts Local Recurrence in Oral Squamous Cell Carcinoma. Indian Journal of Surgical Oncology, 2021, 12, 408-414.	0.3	4
20	Immune checkpoint analysis in lip cancer. Journal of Cranio-Maxillo-Facial Surgery, 2021, 49, 950-958.	0.7	4
21	Molecular Insights into Oral Malignancy. Indian Journal of Surgical Oncology, 2022, 13, 267-280.	0.3	4
22	High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments. Biomedicines, 2021, 9, 1132.	1.4	7
23	Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma. Open Medicine (Poland), 2020, 15, 292-301.	0.6	7
24	PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. Oncotarget, 2017, 8, 112584-112597.	0.8	37
25	The B7 family molecules in oral squamous cell carcinoma: a systematic review. Part I: B7-H1 (PD-L1) and B7-DC (PD-L2). Postepy Dermatologii i Alergologii, 0, , .	0.4	1
26	Desmoglein-3 overexpression in oral squamous cell carcinoma is associated with metastasis formation and early recurrence: An immunohistochemical study. Journal of Cranio-Maxillo-Facial Surgery, 2022, 50, 281-288.	0.7	5
27	Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma. Journal of Applied Oral Science, 2022, 30, e20210344.	0.7	1
28	Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study. Biomedicines, 2022, 10, 710.	1.4	1
29	Expression of PD-L1 is HPV/P16-Independent in Oral Squamous Cell Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
30	Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma. Heliyon, 2022, 8, e10667.	1.4	2